AMIX
Autonomix Medical, Inc. (AMIX) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
Negative net debt to EBITDA and a 4.8x current ratio indicate balance-sheet flexibility versus more levered peers, supporting resilience despite weak profitability.
Debt-to-equity at zero suggests limited structural leverage risk relative to peers, which can preserve financing capacity through cyclical or execution setbacks.
The extremely negative cash conversion cycle implies working-capital funding from suppliers or customers, which can support liquidity efficiency versus peers with longer cash cycles.
Weaknesses
ROIC of -5.2% shows capital is not earning its cost, leaving AMIX structurally behind profitable peers on value creation and reinvestment capacity.
Missing margin disclosure alongside negative ROIC suggests weak operating economics, which typically trails peers with clearer scale and pricing power.
The absence of durable profitability metrics limits evidence of peer-relative operating strength, keeping AMIX exposed to weaker long-term competitive positioning.
Opportunities
If working-capital efficiency remains sustainable, AMIX can free cash for growth or deleveraging faster than peers with less favorable cash cycles.
A strong liquidity position creates room to absorb investment or volatility, which can matter more than peers with tighter near-term funding buffers.
Low leverage leaves more strategic flexibility for future capital allocation, potentially improving positioning if management converts balance-sheet capacity into returns.
Threats
Persistent negative ROIC threatens peer-relative capital efficiency, because competitors with positive returns can compound faster and widen structural gaps over time.
Without margin data, the market may infer weaker pricing power or cost control than peers, increasing vulnerability to competitive pressure.
If the negative cash conversion cycle reflects operational distortion rather than durable efficiency, peers with steadier working-capital profiles may prove more resilient.
Overall Score
AMIX appears structurally weak versus peers because negative capital returns outweigh balance-sheet flexibility, leaving its long-term positioning below more profitable competitors.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Autonomix Medical, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
